Lapatinib

Synonym
Product Category
Product Code
CAS Number
MDL Number
Pubchem CID
Reaxys RN
Lapatinib Ditosylate, Lapatinib base, GSK572016, GW 572016, Tyverb
API & Intermediates
KAPI1F11
231277-92-2
MFCD09264194
208908
10502247
image-155171-Trimethyl(trifluoromethyl)silane_reagent.png
Chemical Name
Molecular Formula
Molecular Weight
Assay
Appearance
Melting Point
Packaging
Storage
Lapatinib
C29H26ClFN4O4S
581.07
≥99%(HPLC)
White to Yellow-Orange Solid
142-146°C
500mg,1g,10g,25g,50g,100g and 500g
-20°C Freezer
Lapatinib (also known as Lapatinib Ditosylate, Lapatinib base, GSK572016, GW 572016, Tyverb) is a selective inhibitor of epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases for the treatment of breast cancer, especially metastatic breast cancer that has progressed after trastuzumab treatment and other chemotherapy.
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. [1]
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. [2]
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. [3]
EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer. [4]
Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors. [5]
Synthesis and biological evaluation of pyrrolopyridazine derivatives as novel HER-2 tyrosine kinase inhibitors. [6]
Synthesis and evaluation of novel pyrimidine-based dual EGFR/Her-2 inhibitors. [7]
Targeted Therapy for Breast Cancer Prevention. [8]
Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis. [9]
References:
[1] F.Ciardiello, et al, Clin. Cancer Res., 2001, 7(10), pp 2958-2970.
[2] G.E.Konecuy, et al, Cancer Res., 2006, 66(3), pp 1630-1639.
[3] C.E.Geyer, et al, N. Engl. Med., 2006, 355(26), pp 2733-2743.
[4] D.E.Gerber, Drug Dev. Res., 2008, 69(6), pp 359-372.
[5] T.R.Rheault, et al, Bioorg. Med. Chem. Lett., 2009, 19(3), pp 817-820.
[6] P.C.Tang, et al, Bioorg. Med. Chem. Lett., 2009, 19(22), pp 6437-6440.
[7] N.SuZuki, et al, Bioorg. Med. Chem. Lett., 2011, 21(6), pp 1601-1606.
[8] P.den Hollander, et al, Front. Oncol., 2013, 3(250), pp 1-15.
[9] T.E.A. Botrel, et al, Core Evid., 2013, 8, pp 69-78.
Signal Word
Hazard Statements
Precautionary Statements
HS Code
RIDADR
Legal Information
Not a dangerous goods



NONH for all modes of transport
Sales restrictions may apply.
1. Product Specification
2. Safety Data Sheet
Please inquire for pricing and availability of this product by writing email to sales@kumidas.com.